CoChat
Sign Up
Cited by 354Alzheimer's disease research and treatmentsGut microbiota and healthNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.

Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition

Open access
Colombo, Alessio Vittorio, Sadler, Rebecca Katie, Llovera, Gemma, Singh, Vikramjeet, Roth, Stefan, Heindl, Steffanie, Sebastian Monasor, Laura, Verhoeven, Aswin, Peters, Finn, Parhizkar, Samira, Kamp, Frits, Gomez de Aguero, Mercedes, MacPherson, Andrew J, Winkler, Edith, Herms, Jochen, Benakis, Corinne, Dichgans, Martin, Steiner, Harald, Giera, Martin, Haass, Christian, Tahirovic, Sabina, Liesz, Arthur·2021·eLife
DOI 10.7554/elife.59826PMC PMC8043748

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Previous studies have identified a crucial role of the gut microbiome in modifying Alzheimer’s disease (AD) progression. However, the mechanisms of microbiome–brain interaction in AD were so far unknown. Here, we identify microbiota-derived short chain fatty acids (SCFA) as microbial metabolites which promote Aβ deposition. Germ-free (GF) AD mice exhibit a substantially reduced Aβ plaque load and markedly reduced SCFA plasma concentrations; conversely, SCFA supplementation to GF AD mice increased the Aβ plaque load to levels of conventionally colonized (specific pathogen-free [SPF]) animals and SCFA supplementation to SPF mice even further exacerbated plaque load. This was accompanied by the pronounced alterations in microglial transcriptomic profile, including upregulation of ApoE. Despite increased microglial recruitment to Aβ plaques upon SCFA supplementation, microglia contained less intracellular Aβ. Taken together, our results demonstrate that microbiota-derived SCFA are critical mediators along the gut-brain axis which promote Aβ deposition likely via modulation of the microglial phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.59826

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Germ-free APPPS1 mice show reduced Alzheimer’s disease (AD) pathology. (A) Representative images and analysis of brain cortices from 5 months old germ-free (GF), naturally recolonized (Rec) and conventionally colonized (specific pathogen-free [SPF]) APPPS1 mice immunostained for Aβ (clone 6E10). Quantification of parenchymal plaque load reveals significantly reduced Aβ burden in GF mice compared to the Rec and SPF groups. Values are expressed as percentages of amyloid plaque area and normalized to GF group (ANOVA; n(GF) = 9, n(Rec) = 6, n(SPF) = 9). (B) Representative results and quantification from Barnes maze behavioral analysis of 5 months old GF, Rec and SPF APPPS1 mice. Quantification of frequency of error zone entering in the Barnes maze reveals a better performance in GF mice compared to Rec and SPF mice (ANOVA; n(GF) = 6, n(Rec) = 8, n(SPF) = 6). (C) Sagittal overview image indicating the analysis ROIs in the frontal cortex (blue: Methoxy-X04-positive plaques) and representative image demonstrating segmentation of Methoxy-X04 fluorescence intensity into individual plaques. The images show maximal intensity projections. Individual plaques are labeled with different colors. (D) Frequency distribution of plaque radius in 5 months old GF and SPF APPPS1 mice (two-way ANOVA; n(GF) = 5, n(SPF) = 5). All data are derived from at least three individual experiments and presented as mean ± SEM.
Figure 1. Germ-free APPPS1 mice show reduced Alzheimer’s disease (AD) pathology. (A) Representative images and analysis of brain cortices from 5 months old germ-free (GF), naturally recolonized (Rec) and conventionally colonized (specific pathogen-free [SPF]) APPPS1 mice immunostained for Aβ (clone 6E10). Quantification of parenchymal plaque load reveals significantly reduced Aβ burden in GF mice compared to the Rec and SPF groups. Values are expressed as percentages of amyloid plaque area and normalized to GF group (ANOVA; n(GF) = 9, n(Rec) = 6, n(SPF) = 9). (B) Representative results and quantification from Barnes maze behavioral analysis of 5 months old GF, Rec and SPF APPPS1 mice. Quantification of frequency of error zone entering in the Barnes maze reveals a better performance in GF mice compared to Rec and SPF mice (ANOVA; n(GF) = 6, n(Rec) = 8, n(SPF) = 6). (C) Sagittal overview image indicating the analysis ROIs in the frontal cortex (blue: Methoxy-X04-positive plaques) and representative image demonstrating segmentation of Methoxy-X04 fluorescence intensity into individual plaques. The images show maximal intensity projections. Individual plaques are labeled with different colors. (D) Frequency distribution of plaque radius in 5 months old GF and SPF APPPS1 mice (two-way ANOVA; n(GF) = 5, n(SPF) = 5). All data are derived from at least three individual experiments and presented as mean ± SEM.CC BY · PubMed Central
Figure 1—figure supplement 1. Sex-specific analysis of amyloid plaque load. Plaque load of animals depicted in Figure 1A was individually analyzed in male (A; n = 5 per group) and female (B; n = 4 per group) mice, revealing a similar trend for increased plaque load in specific pathogen-free (SPF) mice compared to germ-free (GF) mice. Values are expressed as percentages of amyloid plaque area and normalized to GF group (unpaired T-test; at least three individual experiments).
Figure 1—figure supplement 1. Sex-specific analysis of amyloid plaque load. Plaque load of animals depicted in Figure 1A was individually analyzed in male (A; n = 5 per group) and female (B; n = 4 per group) mice, revealing a similar trend for increased plaque load in specific pathogen-free (SPF) mice compared to germ-free (GF) mice. Values are expressed as percentages of amyloid plaque area and normalized to GF group (unpaired T-test; at least three individual experiments).CC BY · PubMed Central
Figure 2. Short chain fatty acids (SCFA) are mediators of Aβ plaque deposition. (A) Plasma SCFA concentrations of acetate, butyrate, and propionate were quantified using GC/MS-based metabolomics analysis, showing an increase in specific pathogen-free (SPF) compared to germ-free (GF) mice (ANOVA; n(GF) = 4, n(Rec) = 5, n(SPF) = 4; two individual experiments). (B) Experimental plan for SCFA supplementation in GF mice. Four weeks old GF mice have been treated with SCFA in drinking water for 8 weeks. (C) Representative images from GF (control-treatment), Rec, and GF supplemented with SCFA mice showing a significant increase in Aβ plaque load upon SCFA administration (ANOVA; n(GF) = 7, n(Rec) = 9, n(GF+SCFA) = 6; three individual experiments). (D) SPF APPPS1 mice were supplemented with control or SCFA in drinking water for 4 weeks (from 8 to 12 weeks of age). Histological analysis revealed a significantly increased plaque load in SCFA-supplemented SPF mice compared to control treatment (unpaired T-test; n(Ctrl) = 4, n(SCFA) = 5; one individual experiment). All data in this figure are presented as mean ± SEM.
Figure 2. Short chain fatty acids (SCFA) are mediators of Aβ plaque deposition. (A) Plasma SCFA concentrations of acetate, butyrate, and propionate were quantified using GC/MS-based metabolomics analysis, showing an increase in specific pathogen-free (SPF) compared to germ-free (GF) mice (ANOVA; n(GF) = 4, n(Rec) = 5, n(SPF) = 4; two individual experiments). (B) Experimental plan for SCFA supplementation in GF mice. Four weeks old GF mice have been treated with SCFA in drinking water for 8 weeks. (C) Representative images from GF (control-treatment), Rec, and GF supplemented with SCFA mice showing a significant increase in Aβ plaque load upon SCFA administration (ANOVA; n(GF) = 7, n(Rec) = 9, n(GF+SCFA) = 6; three individual experiments). (D) SPF APPPS1 mice were supplemented with control or SCFA in drinking water for 4 weeks (from 8 to 12 weeks of age). Histological analysis revealed a significantly increased plaque load in SCFA-supplemented SPF mice compared to control treatment (unpaired T-test; n(Ctrl) = 4, n(SCFA) = 5; one individual experiment). All data in this figure are presented as mean ± SEM.CC BY · PubMed Central
Figure 2—figure supplement 1. Total short chain fatty acids (SCFA) concentrations. Total plasma SCFA concentrations of acetate, butyrate, and propionate in specific pathogen-free (SPF), germ-free (GF), and GF+SCFA treated mice (ANOVA; n(GF) = 5, n(SPF) = 5, n(GF+SCFA) = 4; two individual experiments). Data are presented as mean ± SEM.
Figure 2—figure supplement 1. Total short chain fatty acids (SCFA) concentrations. Total plasma SCFA concentrations of acetate, butyrate, and propionate in specific pathogen-free (SPF), germ-free (GF), and GF+SCFA treated mice (ANOVA; n(GF) = 5, n(SPF) = 5, n(GF+SCFA) = 4; two individual experiments). Data are presented as mean ± SEM.CC BY · PubMed Central
Figure 3. Short chain fatty acids (SCFA) mildly increase amyloidogenic processing. (A) Western blot analysis and (B) its densitometry quantification of 3 months old brain homogenates of control (Ctrl)- and SCFA-supplemented germ-free (GF) APPPS1 animals. The Aβ level is significantly increased in SCFA group in comparison to Ctrl, despite unaffected APP FL levels. APP CTFs show a decreased C83 (**) to C99 (*) ratio. We could not detect alterations in protein levels of secretases involved in APP processing (ADAM10, BACE1, and γ-secretase/PSEN1). m = ADAM10 mature form; im = ADAM10 immature form. Data represent mean ± SEM (unpaired T-test; n(Ctrl) = 3, n(SCFA) = 3). (C) Upper panel: γ-Secretase reconstituted into lipid vesicles was incubated at 37°C together with the C99-based substrate C100-His6 in the presence of increasing doses of a SCFA mixture (375 and 750 μM final concentration of total SCFA of an equimolar mixture of Na-acetate, Na-propionate, and Na-butyrate) for 24 hr. Production of Aβ was analyzed by immunoblotting. γ-Secretase inhibitor (GSI) L-685,458 (0.4 μM) was used as a negative control. No alterations in Aβ levels were detected in the presence of SCFA. Lower panel: Qualitative analysis of individual Aβ species via Tris‐Bicine‐Urea SDS‐PAGE reveals that SCFA treatment does not alter the ratio among the different Aβ species (Aβ37-38-40-42/43) suggesting no direct effects on modulation of γ-secretase cleavage. (D) Aggregation kinetics of monomeric Aβ40 recorded by the increase in fluorescence of Thioflavin T incubated with either 30 mM NaCl (Ctrl) or 30 mM SCFA mixture do not show any significant difference, suggesting that SCFA do not directly modify Aβ fibrillarization. Data points represent mean ± SD from three independent experiments.
Figure 3. Short chain fatty acids (SCFA) mildly increase amyloidogenic processing. (A) Western blot analysis and (B) its densitometry quantification of 3 months old brain homogenates of control (Ctrl)- and SCFA-supplemented germ-free (GF) APPPS1 animals. The Aβ level is significantly increased in SCFA group in comparison to Ctrl, despite unaffected APP FL levels. APP CTFs show a decreased C83 (**) to C99 (*) ratio. We could not detect alterations in protein levels of secretases involved in APP processing (ADAM10, BACE1, and γ-secretase/PSEN1). m = ADAM10 mature form; im = ADAM10 immature form. Data represent mean ± SEM (unpaired T-test; n(Ctrl) = 3, n(SCFA) = 3). (C) Upper panel: γ-Secretase reconstituted into lipid vesicles was incubated at 37°C together with the C99-based substrate C100-His6 in the presence of increasing doses of a SCFA mixture (375 and 750 μM final concentration of total SCFA of an equimolar mixture of Na-acetate, Na-propionate, and Na-butyrate) for 24 hr. Production of Aβ was analyzed by immunoblotting. γ-Secretase inhibitor (GSI) L-685,458 (0.4 μM) was used as a negative control. No alterations in Aβ levels were detected in the presence of SCFA. Lower panel: Qualitative analysis of individual Aβ species via Tris‐Bicine‐Urea SDS‐PAGE reveals that SCFA treatment does not alter the ratio among the different Aβ species (Aβ37-38-40-42/43) suggesting no direct effects on modulation of γ-secretase cleavage. (D) Aggregation kinetics of monomeric Aβ40 recorded by the increase in fluorescence of Thioflavin T incubated with either 30 mM NaCl (Ctrl) or 30 mM SCFA mixture do not show any significant difference, suggesting that SCFA do not directly modify Aβ fibrillarization. Data points represent mean ± SD from three independent experiments.CC BY · PubMed Central
Figure 4. Short chain fatty acids (SCFA) modulate microglia. (A) Morphological analysis of microglia shows an increase in the circularity index, indicating a more activated phenotype, in SCFA- compared to control-treated germ-free (GF) APPPS1 mice. Iba1 (red) has been used as microglial marker. For each group, each shade of color represents the microglia from a single mouse (U test; n(Ctrl) = 6, n(SCFA) = 5). (B) smFISH analysis of microglial cells (red, Cx3cr1 mRNA particles) surrounding amyloid plaques (green, anti-Aβ clone 2D8) shows an increased number of Cx3cr1-positive cells (>4 puncta) clustering around Aβ plaques in SCFA- compared to control-supplemented GF APPPS1 mice. DAPI (blue) was used as nuclear dye (U test; n(Ctrl) = 5, n(SCFA) = 5 mice, 5 FOV per mouse). (C) Experimental outline for APPPS1 brain homogenate injection into a WT mouse brain showing the injection site (red dot). (D) smFISH analysis of Cx3cr1-positive cells (>4 puncta) surrounding the APPPS1 brain homogenate injection site (analysis area relative to injection site for all brains) showing an enhanced recruitment of microglial cells in specific pathogen-free (SPF) versus GF WT mice. (E) APPPS1 brain homogenate injection induces higher microglial activation in SPF in comparison to GF WT mice as shown by the higher amount of Trem2 mRNA puncta (red) per Cx3cr1-positive (green) microglia. DAPI (blue) was used as nuclear dye. In D and E, each different shade of color represents the microglia from a single mouse (U test, n(GF) = 3, n(SPF) = 3; two individual experiments, 120 analyzed images (with multiple microglia) per mouse). (F) Microglial recruitment and Aβ plaque uptake were histologically quantified in SCFA- and control-supplemented SPF APPPS1 mice. Although significantly more CD68-positive (green) and Iba1-positive (red) microglial cells were located at Aβ plaques (white, anti-Aβ clone 3552), the number of Aβ-positive microglia was significantly reduced in the SCFA- compared to the control-treated group. Values are expressed as percentages and normalized to the control-treated group (unpaired T-test; n(Ctrl) = 4, n(SCFA) = 5; one individual experiment).
Figure 4. Short chain fatty acids (SCFA) modulate microglia. (A) Morphological analysis of microglia shows an increase in the circularity index, indicating a more activated phenotype, in SCFA- compared to control-treated germ-free (GF) APPPS1 mice. Iba1 (red) has been used as microglial marker. For each group, each shade of color represents the microglia from a single mouse (U test; n(Ctrl) = 6, n(SCFA) = 5). (B) smFISH analysis of microglial cells (red, Cx3cr1 mRNA particles) surrounding amyloid plaques (green, anti-Aβ clone 2D8) shows an increased number of Cx3cr1-positive cells (>4 puncta) clustering around Aβ plaques in SCFA- compared to control-supplemented GF APPPS1 mice. DAPI (blue) was used as nuclear dye (U test; n(Ctrl) = 5, n(SCFA) = 5 mice, 5 FOV per mouse). (C) Experimental outline for APPPS1 brain homogenate injection into a WT mouse brain showing the injection site (red dot). (D) smFISH analysis of Cx3cr1-positive cells (>4 puncta) surrounding the APPPS1 brain homogenate injection site (analysis area relative to injection site for all brains) showing an enhanced recruitment of microglial cells in specific pathogen-free (SPF) versus GF WT mice. (E) APPPS1 brain homogenate injection induces higher microglial activation in SPF in comparison to GF WT mice as shown by the higher amount of Trem2 mRNA puncta (red) per Cx3cr1-positive (green) microglia. DAPI (blue) was used as nuclear dye. In D and E, each different shade of color represents the microglia from a single mouse (U test, n(GF) = 3, n(SPF) = 3; two individual experiments, 120 analyzed images (with multiple microglia) per mouse). (F) Microglial recruitment and Aβ plaque uptake were histologically quantified in SCFA- and control-supplemented SPF APPPS1 mice. Although significantly more CD68-positive (green) and Iba1-positive (red) microglial cells were located at Aβ plaques (white, anti-Aβ clone 3552), the number of Aβ-positive microglia was significantly reduced in the SCFA- compared to the control-treated group. Values are expressed as percentages and normalized to the control-treated group (unpaired T-test; n(Ctrl) = 4, n(SCFA) = 5; one individual experiment).CC BY · PubMed Central
Figure 4—figure supplement 1. Ex vivo amyloid plaque clearance assay. Primary WT microglia treated with short chain fatty acids (SCFA; 250 µM) do not show alteration in their phagocytic capacity toward Aβ plaques in comparison to the control-treated cells (Ctrl). CD68 (green) was used to visualize microglia. Amyloid plaques were visualized using both Thiazine red (ThR, red, fibrillar Aβ) and an anti-Aβ antibody (3552, white, total Aβ). DAPI (blue) was used as nuclear dye. Values are expressed as percentages of phagocytosed Aβ plaques normalized to the control-treated group and presented as mean ± SEM (unpaired T-test; n(Ctrl) = 3, n(SCFA) = 3; three independent experiments with two technical replicates per experiment).
Figure 4—figure supplement 1. Ex vivo amyloid plaque clearance assay. Primary WT microglia treated with short chain fatty acids (SCFA; 250 µM) do not show alteration in their phagocytic capacity toward Aβ plaques in comparison to the control-treated cells (Ctrl). CD68 (green) was used to visualize microglia. Amyloid plaques were visualized using both Thiazine red (ThR, red, fibrillar Aβ) and an anti-Aβ antibody (3552, white, total Aβ). DAPI (blue) was used as nuclear dye. Values are expressed as percentages of phagocytosed Aβ plaques normalized to the control-treated group and presented as mean ± SEM (unpaired T-test; n(Ctrl) = 3, n(SCFA) = 3; three independent experiments with two technical replicates per experiment).CC BY · PubMed Central
Figure 5. Increased ApoE expression marks microglial activation upon short chain fatty acids (SCFA) supplementation. (A) Heatmap of Nanostring transcriptomic analysis from control- and SCFA-supplemented germ-free (GF) APPPS1 mice at 3 months of age. Row values were scaled using unit variance scaling. Genes previously associated with microglial function have been annotated on the heatmap. Three mice per group have been analyzed. (B) Top 20 upregulated genes in SCFA- versus control-treated samples. Most of transcriptome hits have been previously associated with microglial activation. (C) Functional gene interaction network analysis using Ingenuity Pathway Analysis. Genes are colored based on fold-change values determined by RNA-Seq analysis, where red indicates an increase in SCFA- and green in control-treated animals. Network analysis revealed upregulation of the ApoE-TREM2 axis as one of the principal biological pathways upregulated by SCFA. (D) Representative sagittal brain section indicating location of the analyzed region of interest in the frontal cortex and representative image showing ApoE (green) distribution. Quantification of ApoE signal showed a SCFA-dependent increase of ApoE expression (unpaired T-test; n(Ctrl) = 5, n(SCFA ) = 5; three individual experiments). (E) Quantification of ApoE colocalization (absolute coverage area in mm2) with microglia and astrocytes in control- and SCFA-supplemented GF APPPS1 mice at 3 months of age (unpaired T-test; n(Ctrl) = 5, n(SCFA) = 5; two individual experiments). (F) Analysis of Methoxy-X04-stained brain sections showed a specific increase in plaques of smaller sizes (4–8 µm radius) in 3 months old SCFA- compared to Ctrl-supplemented GF APPPS1 mice (unpaired T-test per bin; n(Ctrl) = 5, n(SCFA) = 5; three individual experiments). Data represent mean ± SEM.
Figure 5. Increased ApoE expression marks microglial activation upon short chain fatty acids (SCFA) supplementation. (A) Heatmap of Nanostring transcriptomic analysis from control- and SCFA-supplemented germ-free (GF) APPPS1 mice at 3 months of age. Row values were scaled using unit variance scaling. Genes previously associated with microglial function have been annotated on the heatmap. Three mice per group have been analyzed. (B) Top 20 upregulated genes in SCFA- versus control-treated samples. Most of transcriptome hits have been previously associated with microglial activation. (C) Functional gene interaction network analysis using Ingenuity Pathway Analysis. Genes are colored based on fold-change values determined by RNA-Seq analysis, where red indicates an increase in SCFA- and green in control-treated animals. Network analysis revealed upregulation of the ApoE-TREM2 axis as one of the principal biological pathways upregulated by SCFA. (D) Representative sagittal brain section indicating location of the analyzed region of interest in the frontal cortex and representative image showing ApoE (green) distribution. Quantification of ApoE signal showed a SCFA-dependent increase of ApoE expression (unpaired T-test; n(Ctrl) = 5, n(SCFA ) = 5; three individual experiments). (E) Quantification of ApoE colocalization (absolute coverage area in mm2) with microglia and astrocytes in control- and SCFA-supplemented GF APPPS1 mice at 3 months of age (unpaired T-test; n(Ctrl) = 5, n(SCFA) = 5; two individual experiments). (F) Analysis of Methoxy-X04-stained brain sections showed a specific increase in plaques of smaller sizes (4–8 µm radius) in 3 months old SCFA- compared to Ctrl-supplemented GF APPPS1 mice (unpaired T-test per bin; n(Ctrl) = 5, n(SCFA) = 5; three individual experiments). Data represent mean ± SEM.CC BY · PubMed Central
Figure 5—figure supplement 1. Effect of individual short chain fatty acids (SCFA) on microglial polarization. Primary microglial cells isolated from specific pathogen-free (SPF) WT mice were cultured and treated with the individual SCFA acetate, butyrate, and propionate, the combined SCFA or the respective control (NaCl). Effect of SCFA on microglial polarization was tested by Nanostring analysis of the microglial transcriptome as in Figure 5 (n = 3 samples per group; data is combined from two individual experiments comparing combined SCFA with Ctrl and individual SCFA to Ctrl, respectively). (A) Heatmap of significantly regulated genes between control and combined SCFA treatment. Row values were scaled using unit variance scaling. (B) Venn diagram for common genes that were significantly regulated (in comparison to the respective salt control) for the individual and combined SCFA treatments. (C) Heatmap for scores of biological processes from gene ontology (GO) analysis (combined scores of p-value and z-score per GO term). Color code indicates min to max values per GO term, and gray color indicates not regulated pathway.
Figure 5—figure supplement 1. Effect of individual short chain fatty acids (SCFA) on microglial polarization. Primary microglial cells isolated from specific pathogen-free (SPF) WT mice were cultured and treated with the individual SCFA acetate, butyrate, and propionate, the combined SCFA or the respective control (NaCl). Effect of SCFA on microglial polarization was tested by Nanostring analysis of the microglial transcriptome as in Figure 5 (n = 3 samples per group; data is combined from two individual experiments comparing combined SCFA with Ctrl and individual SCFA to Ctrl, respectively). (A) Heatmap of significantly regulated genes between control and combined SCFA treatment. Row values were scaled using unit variance scaling. (B) Venn diagram for common genes that were significantly regulated (in comparison to the respective salt control) for the individual and combined SCFA treatments. (C) Heatmap for scores of biological processes from gene ontology (GO) analysis (combined scores of p-value and z-score per GO term). Color code indicates min to max values per GO term, and gray color indicates not regulated pathway.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

Sorted by citations

See all 354

Related

Metadata

Authors
Colombo, A. V., Sadler, R. K., Llovera, G., Singh, V., Roth, S., Heindl, S., Sebastian Monasor, L., Verhoeven, A., Peters, F., Parhizkar, S., Kamp, F., Gomez de Aguero, M., MacPherson, A. J., Winkler, E., Herms, J., Benakis, C., Dichgans, M., Steiner, H., Giera, M., Haass, C., Tahirovic, S., & Liesz, A.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • Institut für Schlaganfall- und Demenzforschung (DE)
  • German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
  • Leiden University Medical Center (NL)
  • Ludwig-Maximilians-Universität München (DE)
  • Maurice Müller Laboratories (DKF), Universitätsklinik für Viszerale Chirurgie und Medizin Inselspital, Bern, Switzerland
  • University Hospital of Bern (CH)
  • Munich Cluster for Systems Neurology (DE)
Corresponding author
Liesz, Arthur
ORCID
Venue
eLife
Publisher
eLife Sciences Publications, Ltd
Published
2021-04-13
Volume
10
ISSN
2050-084X (ISSN-L)
DOI
10.7554/elife.59826
PMC
PMC8043748
OpenAlex
W3153691725
Cited by
354
References
75
Citations by year
2026: 58 · 2025: 82 · 2024: 73 · 2023: 61 · 2022: 61 · 2021: 18
FWCI
33.41
Type
journal article
Language
en
Open access
Licence
Locations
  • eLife (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
  • DZNE Pub (submittedVersion, other-oa)
  • Open Access CRIS of the University of Bern
Funders
  • Vascular Dementia Research Foundation
  • Deutsche Forschungsgemeinschaft (STE847/6-1, HA1737/16-1, EXC 2145 SyNergy - ID 390857198, LI-2534/7-1)
  • H2020 European Research Council (ERC-StG 802305, NMP-2015-686271)
  • Helmholtz Association (Zukunftsthema "Immunology and Inflammation"))
  • NCL Foundation
  • Alzheimer Forschung Initiative (18014)
  • Alzheimer's Association (ADSF-21-831226-C)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
short-chain fatty acids, gut microbiota, Alzheimer's disease, amyloid plaques, microglia, gut-brain axis, germ-free mice, microbial metabolites, apolipoprotein E, microglial phenotype
MeSH terms
Gastrointestinal Microbiome, Alzheimer Disease, Animals, Fatty Acids, Volatile, Female, Male, Specific Pathogen-Free Organisms, Microglia, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review